Tissue protective peptides and uses thereof

Details Tissue protective peptides and uses thereof Tissue protective peptides and uses thereof

2006-08-07

2011-12-06

Tsang, Cecilia J (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S021300, C530S421000

Reexamination Certificate

active

08071554

ABSTRACT:
The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor. The invention is further directed to the consensus sequences for use in engineering a synthetic tissue protective peptide. These tissue protective peptides also include fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO. The invention further encompasses methods for treating or preventing a disease or disorder using tissue protective peptides of the current invention. The invention also encompasses methods for enhancing excitable tissue function using tissue protective peptides of the current invention.

REFERENCES:
patent: 5700909 (1997-12-01), O'Brien
patent: 0 116 446 (1984-08-01), None
patent: 0 410 246 (1991-01-01), None
patent: 1 736 481 (2006-12-01), None
patent: WO/00/61164 (2000-10-01), None
patent: WO/02/053580 (2002-07-01), None
patent: WO/2004/003176 (2004-01-01), None
patent: WO/2004/004656 (2004-01-01), None
patent: WO/2004/096148 (2004-11-01), None
patent: WO/2005/025606 (2005-03-01), None
patent: WO/2005/032467 (2005-04-01), None
patent: WO 2006/119767 (2006-11-01), None
Congote, BBRC., 2004, 324, 673-678.
Skelton, J. Mol. Biol., 2002, 316, 1111-1125.
European Search Report dated Jun. 22, 2009, for European Application No. 06801051.1, filed Aug. 7, 2006.
ISA/US International Search Report dated Jul. 28, 2008, for International Application No. PCT/US2006/031061, filed Aug. 7, 2006.
Noli, N., 1997, “Design, Synthesis and Conformational Analysis of hGM-CSF(13-31)-Gly-Pro-Gly-(103-116),” Journal of Peptide Science, vol. 3:323-335.
Wolfert, M.A., 1998, “Chloroquine and Amphipathic Peptide Helices Show Synergistic Transfection In Vitro,” Gene Therapy, vol. 5:409-411.

Affiliated with

Also associated with

Rating

Tissue protective peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tissue protective peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue protective peptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309594